# Measuring Omalizumab Responses Using Real-world Evidence (MORRE) Study

> **NCT04724278** · — · UNKNOWN · sponsor: **National Jewish Health** · enrollment: 50 (estimated)

## Conditions studied

- Asthma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04724278
- **Lead sponsor:** National Jewish Health
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-05
- **Primary completion:** 2022-07-15
- **Final completion:** 2023-07-15
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2021-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04724278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04724278, "Measuring Omalizumab Responses Using Real-world Evidence (MORRE) Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04724278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*